ACRP blog

NOVEMBER 8, 2023

“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.

Pharmacy 59

Pharmacy Trials Clinical Trials Clinical Trials 59

ACRP blog

NOVEMBER 8, 2023

“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.

Pharmacy 52

Pharmacy Trials Clinical Trials Clinical Trials 52

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. Author’s Bio Akarshika Singh is a business research analyst and competitive intelligence professional.

Protein 40

Protein Gene Production DNA 40

Roots Analysis

FEBRUARY 23, 2024

Advanced treatments, particularly those that focus on the body’s immune system, will require a diverse array of antibodies for research and medicine production. Antibody discovery will play a pivotal role in this ongoing effort for development of antibody-based vaccines, especially for emerging diseases.

Antibody 40

Antibody Research Marketing Scientist 40

Roots Analysis

JANUARY 27, 2025

It is important to note that, for the purpose of subcutaneous biologics market analysis, the biologics were segregated into antibodies , nucleotides, proteins and vaccines. The below figure presents the distribution of subcutaneous biologics based on initial approval year and type of biologic.

Marketing 40

Marketing Drug Delivery Development Protein 40

XTalks

OCTOBER 13, 2020

Despite the Operation Warp Speed COVID-19 vaccine program spearheaded by US President Donald Trump, some of the lead runners in the program — including Moderna and Pfizer — say that data from their vaccine trials won’t be available well into November. Corey said data from other vaccines are expected between January and April.

Vaccine 98

Vaccine Vaccination Trials Manufacturing 98